Search results for "PHARMACOVIGILANCE"

showing 10 items of 50 documents

SP0027 Biosimilars: Potential Clinical Differences and European Regulatory Aspects

2014

Although successful drugs, the use of anti-TNFs is limited by their high cost, and in the present climate of economic difficulty, there is pressure to find alternatives that reproduce their effects at a lower price. Due to their large molecular size and structural complexity, anti-TNFs are impossible to duplicate, unlike smaller, chemically-generated compounds, which can be copied. However, unlike generics, biosimilars are similar rather than identical to the original drugs. Determining the level of similarity that guarantees a comparable efficacy and safety represents a new test for the pharmacological market. Biosimilars of smaller biological molecules, such as somatotropin, EPO and GCSF …

Drugmedicine.medical_specialtyProtein moleculesbusiness.industrymedia_common.quotation_subjectImmunologyBiosimilarPharmacologyGeneral Biochemistry Genetics and Molecular BiologyInfliximabClinical trialRheumatologyMolecular sizePharmacovigilancemedicineImmunology and AllergyIntensive care medicinebusinessPaediatric patientsmedicine.drugmedia_commonAnnals of the Rheumatic Diseases
researchProduct

Therapeutic drug monitoring for antidepressant drug treatment.

2012

The aim of antidepressant drug treatment is to produce remission without causing adverse effects during the acute phase of the illness and to prevent relapses or recurrences during continuation or maintenance therapy. To achieve these goals, drug choice and dosage must be optimized for each patient individually. Therapeutic drug monitoring (TDM), which is based on the assumption that clinical effects correlate better with blood levels than doses, can be helpful. When using tricyclic antidepressant drugs TDM enhances safety and efficacy. For newer antidepressant drugs, however, it is a matter of debate to which extend TDM can have beneficial effects. For many antidepressants there exist care…

Drugmedicine.medical_specialtymedia_common.quotation_subjectCost-Benefit AnalysisPharmacologyDrug CostsDrug treatmentPharmacokineticsMaintenance therapyDrug DiscoveryPharmacovigilancemedicineSecondary PreventionHumansAdverse effectIntensive care medicinemedia_commonPharmacologymedicine.diagnostic_testbusiness.industryDepressionRemission InductionAntidepressive AgentsTreatment OutcomeTherapeutic drug monitoringAntidepressantDrug MonitoringbusinessCurrent pharmaceutical design
researchProduct

Herbal hepatotoxicity: a hidden epidemic

2011

Complementary and alternative therapies, including herbal products, have become increasingly popular in the general population and among patients and physicians. Regulations and pharmacovigilance regarding herbal drugs are still incomplete and need to be improved. In fact, herbals are commonly marketed on the Internet, and in many countries they are sold as food supplements, which are beyond the control of drug regulatory agencies. In Europe and the U.S., reports of hepatotoxicity from these products, including those advertised for liver diseases, are accumulating. Many herbal drugs are also commonly used in children, and in women during pregnancy and lactation, because they are believed to…

Drugmedicine.medical_specialtymedia_common.quotation_subjectPopulationHerb-Drug InteractionsMEDLINEAlternative medicinecomplex mixtureslaw.inventionRandomized controlled trialAcquired immunodeficiency syndrome (AIDS)lawPharmacovigilanceInternal MedicineHumansMedicineMedical prescriptioneducationIntensive care medicineHerbal remedies Dietary supplement Slimming aids Hepatotoxicity Preventionmedia_commoneducation.field_of_studyTraditional medicinebusiness.industrymedicine.diseaseDietary SupplementsEmergency MedicineChemical and Drug Induced Liver InjurybusinessPhytotherapyInternal and Emergency Medicine
researchProduct

Monitoring of Plasma Concentrations of Psychotropic Drugs in Pharmacovigilance

2015

The primary aims of pharmacovigilance are supervision and prevention of medication-related problems under everyday conditions. Pharmacovigilance is an indication for monitoring plasma concentrations, i.e. conducting therapeutic drug monitoring (TDM). Using TDM, it can be clarified if observed unwanted drug effects may be attributed to abnormally high or low drug concentrations. Utmost benefits from TDM are obtained for pharmacovigilance when the method is adequately integrated into the clinical treatment process. How to do this is described in consensus guidelines for TDM in psychiatry. During the last 20 years, TDM was very successful for detection of multiple pharmacokinetic drug-drug int…

Drugmedicine.medical_specialtymedicine.diagnostic_testbusiness.industrymedia_common.quotation_subjectPharmacologyTolerabilityComputerized physician order entryTherapeutic drug monitoringPharmacovigilancePlasma concentrationmedicineRetrospective analysisIntensive care medicinebusinessClinical treatmentmedia_common
researchProduct

Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders.

2021

Introduction The aim of this study was to describe the number and type of drugs used to treat depressive disorders in inpatient psychiatry and to analyse the determinants of potential drug-drug interactions (pDDI) and potentially inappropriate medication (PIM). Methods Our study was part of a larger pharmacovigilance project funded by the German Innovation Funds. It included all inpatients with a main diagnosis in the group of depressive episodes (F32, ICD-10) or recurrent depressive disorders (F33) discharged from eight psychiatric hospitals in Germany between 1 October 2017 and 30 September 2018 or between 1 January and 31 December 2019. Results The study included 14,418 inpatient cases.…

Epidemiologymedicine.medical_treatment0302 clinical medicineRisk FactorsMedicine and Health SciencesAntipsychoticsDrug Interactions030212 general & internal medicineDepression (differential diagnoses)Potentially Inappropriate Medication Listmedia_commonMultidisciplinaryDepressionPharmaceuticsQRDrugsAntidepressantsMiddle AgedAntidepressive AgentsAntidepressant Drug TherapyMedicineAntidepressantDrug Therapy CombinationAntipsychotic AgentsResearch ArticleDrugNeurological Drug Therapymedicine.medical_specialtyPatientsSciencemedia_common.quotation_subject03 medical and health sciencesPharmacotherapyDrug TherapyInternal medicinePharmacovigilanceMental Health and PsychiatrymedicineHumansAntipsychoticProbabilityPolypharmacyPharmacologyInpatientsbusiness.industryMood DisordersOdds ratioHealth CareLogistic ModelsMedical Risk Factorsbusiness030217 neurology & neurosurgeryReceptor Antagonist TherapyPloS one
researchProduct

Adverse reactions to human papillomavirus vaccine in the Valencian Community (2007-2011)

2014

Resumen: Introducción: En 2009, 2 casos de convulsiones en adolescentes tras la administración de la vacuna tetravalente frente al virus del papiloma humano (VPH) generaron impacto mediático y afectaron negativamente la confianza del público en esta vacuna.Nuestros objetivos fueron describir las sospechas de reacciones adversas (SRA) notificadas al Centro Autonómico de Farmacovigilancia de la Comunidad Valenciana (CAFCV) tras la administración de la vacuna frente al VPH y comparar la tasa de notificación de síncope y convulsiones de esta vacuna con la de otras vacunas administradas en adolescentes. Material y métodos: Estudio descriptivo de las notificaciones de SRA relacionadas con esta va…

Human papillomavirusVacunaReacción adversaVirus del papiloma humanoTasa de notificaciónPediatricsRJ1-570Reporting ratePharmacovigilanceFarmacovigilanciaPediatrics Perinatology and Child HealthEnfermeríaAdverse reactionsVaccine
researchProduct

New European legislation on pharmacovigilance

2011

TheEuropeanParliament and theCouncil of the EuropeanUnion have recently adoptedRegulation (EU) No 1235/20101 and Directive 2010/84/EU2 concerning the pharmacovigilance of medicinal products for human use. These and other European institutions have been laying down rules on the subject for decades, but this is the first time they have enacted legislation specifically and (almost) exclusively regulating pharmacovigilance. This paper analyzes the context, causes, objectives, key points and challenges of the new legislation.

Human useHealth PolicyPolitical sciencePharmacovigilanceLegislationContext (language use)Subject (documents)Public administrationDirectivePharmacology Toxicology and Pharmaceutics (miscellaneous)Pharmaceuticals, Policy and Law
researchProduct

French organization for the pharmacovigilance of COVID-19 vaccines: A major challenge.

2021

International audience; In this special issue, we present the main highlights of the first weeks of pharmacovigilance monitoring of coronavirus disease 2019 (COVID-19) vaccines in this unprecedented situation in France: the deployment of a vaccination during an epidemic period with the aim of vaccinating the entire population and the intense pharmacovigilance and surveillance of these vaccines still under conditional marketing authorizations. In this unprecedented situation, the cross approach and interaction between the French pharmacovigilance network and French National Agency for the Safety of Medicines and Health Products (ANSM) has been optimized to provide a real-time safety related …

MaleEuropean levelCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)Adverse drug reactions030226 pharmacology & pharmacyArticleADR adverse drug reaction03 medical and health sciencesPharmacovigilance0302 clinical medicinePharmacovigilancePandemicMedicineAdverse Drug Reaction Reporting SystemsHumansPharmacology (medical)Drug reactionPEG polyethylene glycolEntire populationVaccinesbusiness.industrySOC system organ classSARS-CoV-2COVID coronavirus disease[SCCO.NEUR]Cognitive science/Neuroscience[SCCO.NEUR] Cognitive science/NeuroscienceAuthorizationCOVID-19Middle Agedmedicine.diseaseRPVC Regional Pharmacovigilance CenterVaccinationEMA European Medicines AgencyFemaleMedical emergencyFrancebusinessANSM Agence nationale de sécurité du médicament et des produits de santé (French National Agency for the Safety of Medicines and Health Products)OrganizationTherapie
researchProduct

Risk of bleeding related to selective and non-selective serotonergic antidepressants: a case/non-case approach using data from two pharmacovigilance …

2014

There is increasing evidence for an association between treatment with selective serotonin reuptake inhibitors (SSRI) and an increased risk of bleeding events. The most important underlying mechanism appears to be inhibition of serotonin uptake in platelets, an effect that is also present in antidepressants with non-selective serotonin-reuptake inhibition (NSRI). Accordingly, also NSRI may be associated with an increased risk of bleeding. However, there is little data in this regard.Based on data (spontaneous reports of adverse drug reactions) from 2 pharmacovigilance databases (WHO-database/Vigibase™; BfArM/AkdÄ-database in Germany) we used a case/non-case approach and calculated reporting…

MaleSerotonin uptakeDatabases FactualDrug-Related Side Effects and Adverse ReactionsVenlafaxineHemorrhageSerotonergiccomputer.software_genrePharmacovigilanceDiclofenacSerotonin AgentsSerotonin AgentsGermanyPharmacovigilanceMedicineHumansPharmacology (medical)Databasebusiness.industryDepressionGeneral MedicineOdds ratioAntidepressive AgentsPsychiatry and Mental healthFemalebusinessReuptake inhibitorcomputermedicine.drugPharmacopsychiatry
researchProduct

Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee

2020

Background: To derive a list of opportunistic infections (OI) through the analysis of the juvenile idiopathic arthritis (JIA) patients in the Pharmachild registry by an independent Safety Adjudication Committee (SAC). Methods: The SAC (3 pediatric rheumatologists and 2 pediatric infectious disease specialists) elaborated and approved by consensus a provisional list of OI for use in JIA. Through a 5 step-procedure, all the severe and serious infections, classified as per MedDRA dictionary and retrieved in the Pharmachild registry, were evaluated by the SAC by answering six questions and adjudicated with the agreement of 3/5 specialists. A final evidence-based list of OI resulted by matching …

Malelcsh:Diseases of the musculoskeletal systemBiologic:Paediatrics: 760 [VDP]Artritis infecciosaMedDRAInfants malaltsArthritisSeverity of Illness IndexHospital patientsCohort StudiesPharmacovigilance0302 clinical medicine030212 general & internal medicineRegistriesChildBiologics; Immunosuppressive therapy; Infections; Juvenile idiopathic arthritis; Opportunisticbiologics ; immunosuppressive therapy ; infections ; juvenile idiopathic arthritis ; opportunisticBarneleddgikt3. Good healthImmunosuppressive therapySettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAAntirheumatic AgentsChild PreschoolCohortPediatric Infectious DiseaseFemaleInfectionResearch Articlemedicine.medical_specialtyTuberculosisjuvenil idiopathic arthritisBiologicsOpportunistic InfectionsInfectionsHerpes Zoster03 medical and health sciencesImmunocompromised HostJuvenile idiopathic arthritiInternal medicinePharmacovigilancemedicineHumansTuberculosisbook030203 arthritis & rheumatologyMalalts hospitalitzatsImmunosupressióbusiness.industrySick childrenJuvenile idiopathic arthritismedicine.diseaseRheumatologyArthritis JuvenileInfectious arthritis:Pediatri: 760 [VDP]Orthopedic surgeryOpportunistiske infeksjonerbook.journalOpportunisticlcsh:RC925-935businessInfeccions oportunistesImmunosuppression
researchProduct